SOX9 Antibody - Cancer Stem Cell and Lineage Marker

Introduction to SOX9 Biology

SRY-box transcription factor 9 (SOX9) is a nuclear transcription factor that plays a central role in developmental biology, epithelial differentiation, and lineage specification. It regulates gene expression programs involved in organ development and tissue homeostasis, and its reactivation is frequently observed in disease states, particularly cancer. A SOX9 antibody is widely used to assess nuclear expression patterns associated with progenitor cell populations and differentiation pathways across diverse tissues.

SOX9 in Cancer Stem Cells and EMT

SOX9 is strongly associated with cancer stem cell phenotypes and epithelial-mesenchymal transition (EMT), where it contributes to tumor initiation, cellular plasticity, and resistance to therapy. Elevated SOX9 expression has been reported in pancreatic, colorectal, lung, ovarian, and prostate cancers, often correlating with aggressive tumor behavior. In this context, a SOX9 IHC antibody is commonly used to visualize nuclear staining in tumor cells and progenitor-like compartments, especially in tissue microarray (TMA) studies where large panels of normal and cancer tissues are evaluated side-by-side.

SOX9 Expression in Normal and Tumor Tissues

SOX9 expression is predominantly nuclear, consistent with its function as a transcription factor. In normal tissues, staining is often restricted to epithelial progenitor zones such as pancreatic ducts, intestinal crypts, and other lineage-specific compartments. In tumor tissues, SOX9 expression frequently expands beyond these regions, reflecting dedifferentiation and tumor-associated reprogramming. Tissue microarray-based immunohistochemistry enables direct comparison of SOX9 expression across many tissue types, supporting its use as a marker of lineage identity and tumor progression.

Validated Antibodies for SOX9 Detection

Accurate detection of transcription factors in immunohistochemistry requires highly specific antibodies. Reagents such as SOX9 antibody specificity validated by microarray provide proteome-wide confirmation of target selectivity, supporting clean nuclear staining and reduced background in FFPE tissues. This is particularly important for tissue microarray studies, where consistent performance across hundreds of samples is required for reliable interpretation.

Applications of SOX9 Antibodies

SOX9 antibodies are widely used across multiple experimental platforms. Immunohistochemistry is the primary method for evaluating tissue distribution and nuclear localization, particularly in FFPE sections and TMA formats. Western blotting enables detection of SOX9 protein levels in cell and tissue lysates, with reagents such as SOX9 antibody for western blot supporting biochemical validation of expression patterns. Together, these approaches provide complementary insights into SOX9 biology in both normal and disease contexts.

SOX9 as a Research and Biomarker Target

SOX9 functions downstream of key signaling pathways including Wnt/beta-catenin, Notch, Hedgehog, and TGF-beta, where it regulates transcriptional programs controlling differentiation and cell fate decisions. Its expression is widely studied in cancer biology, where it is linked to tumor progression, stem-like cell populations, and lineage plasticity. The ability to accurately detect SOX9 expression using well-characterized antibodies makes it a valuable tool for studying developmental processes and disease mechanisms.

This SOX9 antibody page is part of a broader antibody panel offered by NSJ Bioreagents.

A selection of SOX9 antibody products is shown below to support a range of research applications.